Weight loss injections are part of a (relatively) new class of drugs called glucagon-like peptide-1 receptor agonists or GLP-1s
There are then two questions to measure the potential impact of these drugs on the food and beverage industry: can the drug makers make users stick longer, and are the effects long-lasting or limited to the use of the medicine
Zhang S, Li Y, Liu X, Guo S, Jiang L, Huang Y, et al
This alteration triggers accelerated growth and invasive potential, but not necessarily progression from horizontal to vertical growth phases
"At this point, I've lost the plot
More on strategic takeaways below: Privia (report, transcript, slides) Privias VBC contracts